Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 4Completed 4Recruiting 2Withdrawn 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 10Esophageal Neoplasms 5Colorectal Neoplasms 5Rectal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Adenocarcinoma Of Esophagus 4Sarcoma 3Lung Neoplasms 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Neoplasms 2Melanoma 2Vomiting 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Peritoneal Metastases From Gastric Cancer 1Peritoneal Metastases From Colorectal Cancer 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Nausea 1Multiple Myeloma 1Malignant mesenchymal tumor 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × Neoadjuvant Therapy × Clear all
NCT00516750 2013-07-10

Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

National Cancer Institute (NCI)

Phase 2 Terminated
100 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡